Other News To Note
Thursday, June 2, 2011
Repligen Corp. completed a pre-new drug application (NDA) meeting with the FDA for its imaging product, RG1068. The Waltham, Mass.-based company is developing RG1068, a synthetic form of human secretin that stimulates the pancreatic ducts to fill with water, for magnetic resonance imaging of the pancreas. The outcome of the meeting was that Repligen will submit its NDA as previously planned.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.